Hemolytic anemia resident survival guide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 147: | Line 147: | ||
* Avoid [[aspirin]] as it reduces the lifecycle of RBCs | * Avoid [[aspirin]] as it reduces the lifecycle of RBCs | ||
* Vaccination against common trigger infections such as [[Hepatitis A]]& [[Hepatitis B|B]] </div>}} | * Vaccination against common trigger infections such as [[Hepatitis A]]& [[Hepatitis B|B]] </div>}} | ||
{{familytree | | | | | | | | | | |!|,|-|-| | {{familytree | | | | | | | | | | |!|,|-|-|^|-|-|.| | | | |}} | ||
{{familytree | | | | | | | | | | |!| H01 | | | H02 | |H01=<div style="float: left; text-align: Center; width: 10em; padding:1em;">'''Negative'''<br> | {{familytree | | | | | | | | | | |!| H01 | | | H02 | |H01=<div style="float: left; text-align: Center; width: 10em; padding:1em;">'''Negative'''<br> | ||
Hereditary spherocytosis</div>|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Positive'''<br> | [[Hereditary spherocytosis]]</div>|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Positive'''<br> | ||
* Autoantibodies | * Autoantibodies | ||
* Alloimmunization | * Alloimmunization | ||
Line 155: | Line 155: | ||
Treatment of drug induced hemolytic anemia includes removal of offending agent</div>}} | Treatment of drug induced hemolytic anemia includes removal of offending agent</div>}} | ||
{{familytree | | | | | | | | | | |!| |!| | |,|-|^|-|.|}} | {{familytree | | | | | | | | | | |!| |!| | |,|-|^|-|.|}} | ||
{{familytree | | | | | | | | | | |!| |!| | | {{familytree | | | | | | | | | | |!| | I01 |!| | | | I02 |I01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Treatment for hereditary spherocytosis'''<br> | ||
* Currently there is no cure for hereditary spherocytosis | |||
* Acute attacks of hemolytic anemia are treated with blood transfusions | |||
* [[Splenectomy]] is indicated in severe cases | |||
* Post-splenectomy, patients are vaccinated against [[influenza]], capsulated bacteria such as ''[[Streptococcus pneumoniae|S. pneumonia]]'' and [[meningococcus]] | |||
* Cholecystectomy is indicated in patients with pigment gallstones</div>|I02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Alloimmunisation treatment'''<br> | |||
Causes: ABO incompatible or Rh incompatible transfusion | Causes: ABO incompatible or Rh incompatible transfusion | ||
* Stop transfusion immediately | * Stop transfusion immediately | ||
Line 163: | Line 168: | ||
* [[Hemodialysis]] | * [[Hemodialysis]] | ||
* If DIC occurs then treatment with [[fresh frozen plasma]], [[platelet transfusion]] or [[cryoprecipitate]]</div>}} | * If DIC occurs then treatment with [[fresh frozen plasma]], [[platelet transfusion]] or [[cryoprecipitate]]</div>}} | ||
{{familytree | | | | | | | | | | |!| | |,|-|^|-|-|-|.|}} | |||
{{familytree | | | | | | | | | | |!| | J01 | | | | J02 |J01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Warm type AIHA'''<br> | |||
* First-line treatment: [[Corticosteroids]] | |||
* If anemia does not improve with corticosteroids, other [[immunosuppressant]]s may be considered | |||
* Second-line: [[Rituximab]], [[cyclophosphamide]], [[azathioprine]], [[cyclosporine]] | |||
* Splenectomy in recurrent disease|J02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cold type AIHA'''<br> | |||
* Avoid cold exposure | |||
* [[Rituximab]] in severe or recurrent disease | |||
* Treat underlying infection</div>}} | |||
{{familytree | | | | | | | | | | K01 |K01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''[[Thrombotic thrombocytopenic purpura]]'''<br> | |||
* Transfusion is '''[[contraindicated]]''' | |||
* [[Plasmapheresis]] is treatment of choice | |||
* [[Fresh frozen plasma]] can be given if plasmapheresis is not available | |||
* Corticosteroids are given concomitantly | |||
* [[Rituximab]] is emerging as a therapy when plasma exchange and corticosteroids fail | |||
* Refractory TTP is treated with immunosuppressive agents such as [[cyclophosphamide]] and [[vincristine]] | |||
* Caplacizumab is another treatment option but it is associated with excess bleeding | |||
'''[[Hemolytic uremic syndrome]]'''<br> | |||
* Treatment of HUS mainly focus on supportive care | |||
* Steroids | |||
* [[Hemodialysis]] | |||
* [[Plasmapheresis]] | |||
* Blood transfusion when necessary | |||
'''[[Disseminated intravascular coagulation]]'''<br> | |||
* [[Platelet]] transfusion | |||
* [[Fresh frozen plasma]] | |||
* [[Cryoprecipitate]] | |||
'''[[HELLP syndrome]]'''<br> | |||
* Immediate delivery of the baby | |||
* Corticosteroids may be used | |||
'''[[Malignant hypertension]]''' | |||
* Careful lowering of mean arterial pressure over 8 hours | |||
* Parenteral antihypertensive agents such as [[labetalol]], [[nicardipine]], [[sodium nitroprusside]] etc | |||
'''[[Paroxysmal nocturnal hemoglobinuria]]'''<br> | |||
* Blood transfusions in severe anemia | |||
* Prevention of [[thrombosis]] with [[warfarin]] | |||
* [[Eculizumab]] </div>}} | |||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 14:58, 5 August 2020
Hemolytic anemia Resident Survival Guide |
---|
Overview |
Causes |
FIRE |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Overview
- Anemia is defined as a decrease in red blood cell population in the body. Hemolytic anemia results from a premature destruction of RBCs.
- Hemolysis can be due to either extravascular or intravascular destruction of cells[1].
- It is caused due to a wide variety of reasons which include inherited diseases like thalassemia, sickle cell disease etc, infections, autoimmune conditions, bone marrow dysfunction, blood transfusions and certain drugs can also result in hemolytic anemia [2].
- Most common presenting symptoms are fatigue, palpitations, dyspnea, tachycardia and icterus in severe cases.
- Diagnosis usually requires a battery of tests including, but not limited to a peripheral smear, CBC, serum LDH, bone marrow studies, etc.
- Treatment is directed by the specific cause and can involve bone marrow transplant, splenectomy, transfusions etc[3].
Causes
Life threatening causes
- ABO incompatibility
- Disseminated intravascular coagulation
- Thrombotic thrombocytopenic purpura
- Hemolytic uremic syndrome
- Pre-eclampsia and malignant hypertension
Other causes
- Membrane cytoskeletal defects like hereditary spherocytosis and hereditary elliptocytosis [4]
- Glucose 6 phosphate dehydrogenase deficiency
- Pyruvate kinase deficiency
- Sickle cell disease
- Thalassemia
- Cold agglutinin disease
- Drug induced hemolytic anemia
- Systemic lupus erythematosus
- Prosthetic heart valves
- Infectious causes such as malaria, hepatitis, CMV infection etc.
For a complete list of hemolytic anemia causes click here
Diagnosis
The approach to diagnosis of hemolytic anemia is based on a step-wise testing strategy. Below is an algorithm summarising the identification and laboratory diagnosis of hemolytic anemia.
Characterize the symptoms: ❑ Weakness ❑ Shortness of breath ❑ Jaundice ❑ Lethargy ❑ Chest pain and reduced exercise tolerance ❑ Pica | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Tachypnea ❑ Cold and clammy skin ❑ Hypotension ❑ HEENT signs:
❑ Fever and neurological signs are seen in TTP ❑ Hemoglobinuria in some cases | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initial workup for hemolysis: ❑ Indirect bilirubin ❑ serum haptoglobin ❑ Lactate dehydrogenase level ❑ Reticulocyte count ❑ Urinalysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No laboratory evidence of hemolysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consider differential diagnosis ❑ Iron deficiency anemia ❑ Anemia of chronic disease ❑ Vitamin B12 deficiency ❑ Folate deficiency | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Degmacytes | Normal cell morphology | Spherocytes | Elliptocytes | Shistocytes | Sickle shaped cells | Hypochromic, microcytic cells | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
G6PD deficiency | Sickle cell disease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
H/o exercise, exertion, trauma or surgery? | Beta thalassemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative | Positive | No | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD55/59 | ❑ Drug induced hemolytic anemia ❑ Autoimmune disease | ❑Exercise induced hemolysis ❑Prosthetic heart valve ❑Severe aortic stenosis | Microangiopathic hemolytic anemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Positive | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-eclampsia and eclampsia | Recent diarrhea | Decreased ADAMTS13 activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria | Hereditary spherocytosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HELLP syndrome | Hemolytic uremic syndrome | Thrombotic thrombocytopenic purpura | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment
- The treatment of hemolytic anemia depends on the cause of anemia.[5][6][7]
- Treatment plan is summarized in the algorithm below based on the 2017 guidelines published by the British Society of Hematology and[8] and the 2020 recommendations by the First International Consensus Group.[9]
History
Physical examination
| |||||||||||||||||||||||||||||||||||||||||||||
Confirm hemolysis
| |||||||||||||||||||||||||||||||||||||||||||||
Peripheral blood smear findings | |||||||||||||||||||||||||||||||||||||||||||||
Bite cells | |||||||||||||||||||||||||||||||||||||||||||||
Oxidative stress like
| |||||||||||||||||||||||||||||||||||||||||||||
Further investigations
| Treatment of acute attacks Long term measures
| ||||||||||||||||||||||||||||||||||||||||||||
Negative Hereditary spherocytosis | Positive
| ||||||||||||||||||||||||||||||||||||||||||||
Treatment for hereditary spherocytosis
| Alloimmunisation treatment Causes: ABO incompatible or Rh incompatible transfusion
| ||||||||||||||||||||||||||||||||||||||||||||
Warm type AIHA
| Cold type AIHA | ||||||||||||||||||||||||||||||||||||||||||||
Thrombotic thrombocytopenic purpura
Disseminated intravascular coagulation
Paroxysmal nocturnal hemoglobinuria
| |||||||||||||||||||||||||||||||||||||||||||||
Do's
Don'ts
References
- ↑ Phillips J, Henderson AC (2018). "Hemolytic Anemia: Evaluation and Differential Diagnosis". Am Fam Physician. 98 (6): 354–361. PMID 30215915.
- ↑ Renard D, Rosselet A (2017). "Drug-induced hemolytic anemia: Pharmacological aspects". Transfus Clin Biol. 24 (3): 110–114. doi:10.1016/j.tracli.2017.05.013. PMID 28648734.
- ↑ Morishita E (2015). "[Diagnosis and treatment of microangiopathic hemolytic anemia]". Rinsho Ketsueki. 56 (7): 795–806. doi:10.11406/rinketsu.56.795. PMID 26251142.
- ↑ Barcellini W, Bianchi P, Fermo E, Imperiali FG, Marcello AP, Vercellati C; et al. (2011). "Hereditary red cell membrane defects: diagnostic and clinical aspects". Blood Transfus. 9 (3): 274–7. doi:10.2450/2011.0086-10. PMC 3136593. PMID 21251470.
- ↑ Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y; et al. (2017). "Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan". Int J Hematol. 106 (1): 3–15. doi:10.1007/s12185-017-2264-7. PMID 28550351.
- ↑ Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J; et al. (2019). "Hemolytic uremic syndrome in a developing country: Consensus guidelines". Pediatr Nephrol. 34 (8): 1465–1482. doi:10.1007/s00467-019-04233-7. PMID 30989342.
- ↑ Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH; et al. (2014). "Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members". JAMA. 312 (10): 1033–48. doi:10.1001/jama.2014.10517. PMID 25203083.
- ↑ Kamesaki T (2019). "[Progress in diagnosis and treatment of autoimmune hemolytic anemia]". Rinsho Ketsueki. 60 (9): 1100–1107. doi:10.11406/rinketsu.60.1100. PMID 31597833.
- ↑ Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA; et al. (2020). "Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting". Blood Rev. 41: 100648. doi:10.1016/j.blre.2019.100648. PMID 31839434.